GlassScriptPhysician profile
Sonia Kim
NPI 1558525840
$6,728.49
in general payments reported to CMS, 2019-2025
27 companies · $1,133 in 2025
The $1,133 reported for 2025 was more than what 91% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.13 · 2020: $117 · 2021: $1,198 · 2022: $2,747 · 2023: $774 · 2024: $686 · 2025: $1,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,394 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,393.60 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,407.05 | 2020-2023 | |
| Mayne Pharma Commercial LLC | $696.51 | 2022-2025 | |
| Astellas Pharma US INC | $627.68 | 2023-2025 | Veozah, Myrbetriq |
| Therapeuticsmd, INC. | $457.89 | 2021-2022 | |
| Exeltis, USA INC. | $432.03 | 2021-2025 | Slynd |
| Daiichi Sankyo INC. | $427.26 | 2022-2023 | Injectafer |
| Avion Pharmaceuticals | $393.14 | 2021-2023 | Balcoltra |
| Agile Therapeutics, INC. | $382.20 | 2021-2023 | Twirla |
| Coopersurgical, INC. | $258.92 | 2021-2025 | Paragard T 380a, Endosee |
| Shield Therapeutics INC | $247.70 | 2023-2025 | Accrufer |
| Aspira Women'S Health INC | $201.51 | 2022 | |
| Myovant Sciences INC. | $194.16 | 2022 | |
| Evofem Biosciences, INC. | $171.42 | 2021-2022 | |
| Scynexis, INC. | $161.62 | 2022 | |
| Mindray Ds USA, INC. | $109.64 | 2025 | Te X, Te7 Max |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $109.56 | 2023 | Myrisk |
| Biogen, INC. | $95.48 | 2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $91.63 | 2023-2025 | Myfembree |
| Lupin INC. | $69.80 | 2019-2020 | |
| Organon LLC | $64.54 | 2021-2025 | Nexplanon |
| Glaxosmithkline, LLC. | $29.05 | 2020-2022 | |
| Hologic Sales and Service, LLC | $26.33 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.07 | 2025 | |
| Urovant Sciences INC | $18.15 | 2022 | |
| Merck Sharp & Dohme LLC | $13.26 | 2021 | |
| Pfizer INC. | $11.90 | 2022 | |
| Dysis Medical, INC. | $10.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.